Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death.

The clinical response to antitumor therapy is measured using imaging, such as CT or MRI, 6-12 weeks following chemotherapy treatment. The images at that time reflect both tumor cell death and new growth. Therefore, the amount of tumor cell death caused by chemotherapy cannot be efficiently quantified with current imaging modalities. A quantitative measurement of tumor cell death immediately following chemotherapy is needed to help validate both new agents and to optimize administration of existing therapies. Annexin V is a 36kD protein that binds to exposed phosphatidylserine (PS) on dying cells. In order to synthesize a probe that can detect cell death in vivo, the positron emitter F-18 was conjugated to annexin V via the compound N- succinimidyl-4-[18F]fluorobenzoate, [18F]SFB. The decay corrected radiochemical yield of F-18 labeled annexin V from 18F fluoride was 17.6 +/- 5.6% (n = 4) in three hours. The stepwise radiochemical yield of the conjugation step with annexin V was as high as 70% when a protein concentration of 5 mg/ml was used. Cancer cells treated with the chemotherapeutic agent, etoposide, showed an 88% increase in the binding of F-18 labeled annexin V compared to untreated cells. We conclude that [18F] labeled annexin V can be readily prepared by the conjugation of annexin V with [18F]SFB and that the positron-emitting compound is biologically active in detecting apoptosis.

[1]  R. Davis,et al.  In vivo detection and imaging of phosphatidylserine expression during programmed cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Reutelingsperger,et al.  Flow cytometry of apoptotic cell death. , 2000, Journal of immunological methods.

[3]  M. Zalutsky,et al.  Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. , 1994, Bioconjugate chemistry.

[4]  P. Doevendans,et al.  Visualisation of cell death in vivo in patients with acute myocardial infarction , 2000, The Lancet.

[5]  F. Blankenberg,et al.  99mTc Annexin V Imaging of Neonatal Hypoxic Brain Injury , 2000, Stroke.

[6]  R. Davis,et al.  Imaging of apoptosis (programmed cell death) with 99mTc annexin V. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  F. Blankenberg,et al.  Dying a thousand deaths. Radionuclide imaging of apoptosis. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[8]  P. Edwards The Impact of Developmental Biology on Cancer Research: An Overview , 2004, Cancer and Metastasis Reviews.

[9]  D. Green,et al.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl , 1995, The Journal of experimental medicine.

[10]  W Burchert,et al.  Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. , 2003, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[11]  C. Reutelingsperger,et al.  Expression on B Cells Undergoing Apoptosis Annexin V for Flow Cytometric Detection of Phosphatidylserine , 2022 .

[12]  W. MacLellan,et al.  Death by design. Programmed cell death in cardiovascular biology and disease. , 1997, Circulation research.

[13]  M. Israel,et al.  Cytogenetic characterization of selected small round cell tumors of childhood. , 1986, Cancer genetics and cytogenetics.

[14]  D. Podoloff,et al.  In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. , 2001, Cancer biotherapy & radiopharmaceuticals.

[15]  Nagara Tamaki,et al.  Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-annexin V. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  D. Gibson,et al.  Development of annexin V mutants suitable for labeling with Tc(i)-carbonyl complex. , 2002, Bioconjugate chemistry.

[17]  F. Blankenberg,et al.  Development and characterization of annexin V mutants with endogenous chelation sites for (99m)Tc. , 2000, Bioconjugate chemistry.

[18]  J. Tait,et al.  Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. , 1990, The Journal of biological chemistry.

[19]  F. Blankenberg,et al.  Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. , 2000, Radiology.

[20]  F. Blankenberg,et al.  Annexin-V imaging for noninvasive detection of cardiac allograft rejection , 2001, Nature Medicine.

[21]  P. Doevendans,et al.  Markers of apoptosis in cardiovascular tissues: focus on Annexin V. , 2000, Cardiovascular research.

[22]  M. Cerqueira,et al.  Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. , 1995, Circulation.

[23]  R A Hawkins,et al.  A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  A. Harris,et al.  Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.

[25]  H. Coenen,et al.  Fluoroacylation agents based on small n.c.a. [18F]fluorocarboxylic acids , 1994 .

[26]  F. Blankenberg,et al.  Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis , 1999, European Journal of Nuclear Medicine.